VTYX Q3 2024 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$39M

Net Income

-$35M

EPS (Diluted)

$-0.50

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$301M

Total Liabilities

$22M

Stockholders' Equity

$279M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$39M	-$58M	+33.5%
Net Income	-$35M	-$54M	+34.8%